• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by AbCellera Biologics Inc.

    10/9/24 10:20:31 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABCL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)*


    AbCellera Biologics Inc.

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    00288U106

    (CUSIP Number)


    09/30/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00288U106


    1Names of Reporting Persons

    BAILLIE GIFFORD & CO
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    9,677,624.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    12,894,703.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    12,894,703.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    AbCellera Biologics Inc.
    (b)Address of issuer's principal executive offices:

    2215 YUKON STREET, 2215 YUKON STREET, VANCOUVER, BRITISH COLUMBIA, CANADA, V5Y 0A1.
    Item 2. 
    (a)Name of person filing:

    Baillie Gifford & Co
    (b)Address or principal business office or, if none, residence:

    Calton Square 1 Greenside Row Edinburgh EH1 3AN Scotland UK
    (c)Citizenship:

    Scotland UK
    (d)Title of class of securities:

    Ordinary Shares
    (e)CUSIP No.:

    00288U106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Investment adviser
    Item 4.Ownership
    (a)Amount beneficially owned:

    12,894,703
    (b)Percent of class:

    4.38%  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    9,677,624

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    12,894,703

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to investment advisers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BAILLIE GIFFORD & CO
     
    Signature:Grant Meikle
    Name/Title:Threshold & Transaction Reporting Manager
    Date:10/09/2024
    Get the next $ABCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    11/7/2025$4.00Outperform → Market Perform
    Leerink Partners
    7/7/2025$5.00Outperform
    Leerink Partners
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    10/13/2023$20.00Overweight
    Piper Sandler
    2/28/2023Outperform
    Cowen
    More analyst ratings

    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AbCellera Biologics downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded AbCellera Biologics from Outperform to Market Perform and set a new price target of $4.00

    11/7/25 8:27:29 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners resumed coverage on AbCellera Biologics with a new price target

    Leerink Partners resumed coverage of AbCellera Biologics with a rating of Outperform and set a new price target of $5.00

    7/7/25 8:15:34 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics downgraded by The Benchmark Company

    The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

    8/20/24 6:47:45 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Booth Andrew

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    1/5/26 12:11:53 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Hansen Carl L. G.

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    1/5/26 12:10:55 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Legal Officer Stimart Tryn

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    1/5/26 12:10:22 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbCellera to Present at Upcoming Investor Conferences in March and April 2026

    AbCellera (NASDAQ:ABCL) today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference, March 4, 2026 KeyBanc Capital Markets Healthcare Forum, March 17, 2026 Bloom Burton & Co. Healthcare Investor Conference, April 21-22, 2026 A live audio webcast of each presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website closer to date. A replay will be available through the same link following the presentation. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines i

    2/11/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

    AbCellera (NASDAQ:ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please v

    1/22/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

    AbCellera (NASDAQ:ABCL) today announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635. ABCL635 is a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. The transition to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from healthy volunteers from the Phase 1 portion of the study. The Phase 2 portion is a multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of ABCL635 in reducing the frequency and severity of VMS in 80 postmenopausal women. "Advancing this program into P

    1/12/26 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    SEC Filings

    View All

    AbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    1/14/26 5:09:38 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    12/18/25 2:43:39 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    11/28/25 2:20:38 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Montalbano John S. bought $178,460 worth of shares (50,000 units at $3.57), increasing direct ownership by 29% to 221,000 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    11/26/25 2:58:20 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/11/25 6:42:57 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/10/25 5:11:03 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Financials

    Live finance-specific insights

    View All

    AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

    AbCellera (NASDAQ:ABCL) will announce its full year 2025 financial results on Tuesday, February 24, 2026, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please v

    1/22/26 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Reports Q3 2025 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the third quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "AbCellera successfully delivered on two corporate priorities this quarter by starting activities at our new clinical manufacturing facility and substantially completing our platform investments," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We ended the quarter with approximately $680 million dollars in available liquidity to execute on our strategy and will continue to prioritize advancing our two lead programs through Phase 1 clinical studies and building our pipeline." Q3 2025 Busine

    11/6/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

    AbCellera (NASDAQ: ABCL) will announce its third quarter 2025 financial results on Thursday, November 6, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, pl

    9/29/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Leadership Updates

    Live Leadership Updates

    View All

    AbCellera Appoints Dr. Stephen Quake to its Board of Directors

    AbCellera (NASDAQ:ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse fields, including single molecule biophysics, microfluidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. "We are pleased to welcome Dr. Quake to AbCellera's Board of Directors. His presence reinforces our commitment to excellence in science and technology," said Carl Hansen, Ph.D., fo

    11/10/25 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Announces Resignation of Board Member

    AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

    2/23/24 4:30:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

    TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

    6/13/23 7:59:57 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    11/14/24 4:11:49 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AbCellera Biologics Inc.

    SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

    2/14/24 4:21:54 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    2/13/24 5:01:32 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care